Our Take
The delay signals FDA scrutiny of starting doses, not maintenance therapy, suggesting safety questions around the more convenient weekly injection protocol.
Why it matters
Alzheimer's patients and caregivers face continued reliance on 18-month IV infusion protocols. The delay affects adoption timelines for the only approved amyloid-clearing therapy.
Do this week
Neurologists: adjust patient expectations for subcutaneous Leqembi availability and prepare IV infrastructure through August.
FDA requests major amendments to Leqembi subcutaneous filing
The FDA delayed approval of Biogen and Eisai's subcutaneous version of Alzheimer's drug Leqembi by three months, pushing the decision date to August 24. The agency classified additional information requests as a "major amendment" to the companies' filing for Leqembi Iqlik as an initial weekly therapy.
The subcutaneous version is already approved as maintenance therapy following 18 months of intravenous infusions. The companies sought approval for weekly subcutaneous injections as the starting treatment, eliminating the IV requirement entirely.
Pierre Fabre separately announced FDA alignment on a resubmission path for twice-rejected cell therapy Ebvallo. The agency agreed that single-arm study data with historical controls would suffice for the post-organ transplant malignancy treatment. Argenx named COO Karen Massey as CEO, replacing co-founder Tim Van Hauwermeiren after 16 years. Blackstone Life Sciences invested $250 million in Anagram Therapeutics for pancreatic enzyme replacement therapy ANG003.
Convenience drives Alzheimer's treatment adoption
The delay extends patient dependence on IV infusion centers for Leqembi initiation. Weekly subcutaneous dosing would eliminate the 18-month IV requirement and reduce healthcare system burden. Leqembi remains the only approved amyloid-clearing therapy, making delivery method changes significant for patient access.
The FDA noted no approvability concerns to date (per company statement), suggesting the delay addresses dosing protocols rather than fundamental safety issues. The timing affects competitive positioning against upcoming Alzheimer's treatments in development.
Prepare for extended IV protocols
Neurologists should adjust patient counseling around subcutaneous availability and maintain IV infusion capacity through August. The delay does not affect current maintenance therapy approvals for patients completing the 18-month IV protocol.
The Pierre Fabre regulatory alignment on Ebvallo demonstrates FDA flexibility on historical controls for rare post-transplant malignancies, potentially relevant for other cell therapy developers facing similar regulatory paths.